Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Qilu Hospital of Shandong University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1890-01-01

Employees: -

Market Cap: -

Website: https://www.qiluhospital.com

Clinical Trials

Virtual Reality's Impact on Upper Limb Function in Post-stroke Patients

Not Applicable

Not yet recruiting

Conditions: Stroke

First Posted Date: 2025-03-18

Last Posted Date: 2025-03-18

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 120

Registration Number: NCT06881680

Locations: 🇨🇳
Qilu hospital, Jinan, Shangdong, China

Single Cell Landscape of HBV-related Acute-on-chronic Liver Failure Patients

Recruiting

Conditions: HBV Related Acute-on-chronic Liver Failure

First Posted Date: 2025-03-10

Last Posted Date: 2025-03-10

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 21

Registration Number: NCT06865859

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Plasma Proteomics Study of End-Stage Liver Disease Patients Based on Olink Technology

Active, not recruiting

Conditions: HBV Related Acute-on-chronic Liver Failure

First Posted Date: 2025-03-10

Last Posted Date: 2025-03-10

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 58

Registration Number: NCT06865898

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

Not Applicable

Recruiting

Conditions: Pneumonia, Ventilator-Associated

Interventions: Drug: Colistimethate sodium (CMS)

First Posted Date: 2025-02-19

Last Posted Date: 2025-06-15

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 476

Registration Number: NCT06834971

Locations: 🇨🇳
Qilu Hospital of Shandong university, Jinan, Shandong, China

Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites

Phase 1

Recruiting

Conditions: Cancer of Stomach, Adenocarcinoma
Ascites, Malignant

Interventions: Drug: zoledronic acid plus Sintilimab intraperitoneal injection

First Posted Date: 2025-01-06

Last Posted Date: 2025-01-06

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 24

Registration Number: NCT06759064

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

The Impact of Methylene Blue on the Quality of Recovery in Patients Undergoing Hemorrhoidectomy

Recruiting

Conditions: Hemorrhoidectomy
Postoperative Analgesia

First Posted Date: 2024-12-24

Last Posted Date: 2025-02-17

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 290

Registration Number: NCT06747195

Locations: 🇨🇳
Heze Hospital of Traditional Chinese Medicine, Heze, Shandong, China
🇨🇳
Qilu hospital of Shandong University, Jinan, Shandong, China
🇨🇳
Weifang People's Hospital, Weifang, Shandong, China

Risk Factors for Complications After Cranioplasty

Recruiting

Conditions: Cranioplasty
Postoperative Complications
Risk Assessment

First Posted Date: 2024-12-18

Last Posted Date: 2025-06-05

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 1000

Registration Number: NCT06740773

Locations: 🇨🇳
Department of Neurosurgery, Daping Hospital of Army Medical University, Chongqing, Chongqing, China
🇨🇳
Department of Neurosurgery, Tang-Du Hospital, Xi'an, Shaanxi, China
🇨🇳
Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong, China

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Fluzoparib
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 105

Registration Number: NCT06735326

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2

Recruiting

Conditions: HER2-positive Gastric Cancer
Metastatic Gastric Cancer
Unresectable Gastric Carcinoma

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: S-1
Drug: Capecitabine
Drug: 5-FU
Drug: Cisplatin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-31

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 110

Registration Number: NCT06730373

Locations: 🇨🇳
Shandong Univerisity Qilu Hospital, Jinan, Shandong, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China

and more 17 locations

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Recruiting

Conditions: Advanced Gastric Cancer
Locally Advanced Gastric Carcinoma

Interventions: Drug: ICI plus Chemothearpy
Drug: Chemotherapy

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 500

Registration Number: NCT06727981

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy